Zynex (NASDAQ:ZYXI) Releases Q4 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its fourth quarter 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.090- for the period, compared to the consensus estimate of 0.100. The company issued revenue guidance of $53.6 million-, compared to the consensus revenue estimate of $53.3 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada decreased their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Zynex in a report on Wednesday, September 4th.

Zynex Stock Up 2.8 %

NASDAQ ZYXI traded up $0.23 on Thursday, hitting $8.59. 151,606 shares of the stock traded hands, compared to its average volume of 173,447. The stock has a 50-day moving average of $7.96 and a 200 day moving average of $9.23. Zynex has a twelve month low of $7.04 and a twelve month high of $13.77. The company has a market capitalization of $272.65 million, a P/E ratio of 47.72 and a beta of 0.54. The company has a current ratio of 4.06, a quick ratio of 3.22 and a debt-to-equity ratio of 1.79.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). Zynex had a net margin of 3.12% and a return on equity of 14.15%. The firm had revenue of $49.88 million for the quarter, compared to analyst estimates of $51.99 million. During the same quarter in the previous year, the company earned $0.09 EPS. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. As a group, analysts expect that Zynex will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Zynex

In other news, Director Joshua R. Disbrow acquired 7,000 shares of the business’s stock in a transaction on Monday, July 29th. The shares were purchased at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the purchase, the director now directly owns 72,000 shares of the company’s stock, valued at $599,040. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Anna Lucsok sold 8,083 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the transaction, the chief operating officer now directly owns 16,980 shares of the company’s stock, valued at $136,349.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Joshua R. Disbrow acquired 7,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, with a total value of $58,240.00. Following the completion of the acquisition, the director now directly owns 72,000 shares in the company, valued at approximately $599,040. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 52.13% of the stock is currently owned by insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.